| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 2.740 | 3.731 | 5.361 | 6.227 | 4.022 | 34.220 | 68.834 |
| Total Income - EUR | - | - | 0 | 2.740 | 3.731 | 5.361 | 6.227 | 4.022 | 34.220 | 68.834 |
| Total Expenses - EUR | - | - | 0 | 4.334 | 3.899 | 7.241 | 7.705 | 15.807 | 22.199 | 14.204 |
| Gross Profit/Loss - EUR | - | - | 0 | -1.594 | -168 | -1.879 | -1.478 | -11.785 | 12.021 | 54.630 |
| Net Profit/Loss - EUR | - | - | 0 | -1.676 | -280 | -2.040 | -1.665 | -11.906 | 12.021 | 46.506 |
| Employees | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Sphynx Medicine S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 27 | 0 | 474 | 20.137 | 14.418 | 9.762 | 4.452 | 17 |
| Current Assets | - | - | 127 | 1.355 | 21.928 | 997 | 5.741 | 5.995 | 15.144 | 32.884 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 453 | 3.800 | 4.358 | 0 |
| Receivables | - | - | 0 | 231 | 21.838 | 0 | 0 | 1.418 | 824 | 13.324 |
| Cash | - | - | 127 | 1.124 | 90 | 997 | 5.288 | 776 | 9.962 | 19.560 |
| Shareholders Funds | - | - | 44 | -1.633 | -1.881 | -3.879 | -5.458 | -17.381 | -5.294 | 30.142 |
| Social Capital | - | - | 44 | 43 | 42 | 48 | 46 | 47 | 59 | 58 |
| Debts | - | - | 109 | 3.082 | 24.511 | 25.303 | 25.690 | 33.210 | 25.127 | 2.759 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Sphynx Medicine S.r.l.